The Ministry of Food and Drug Safety approved the new drug for chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), ‘Bosulif (bosutinib)’ in Korea. The drug was first approved in the US in 2012. With the approval, the treatment options for Ph+CML increased to 6, excluding the first-generation drug.

According to industry sources on the 14th, the MFDS approved 3 dosages (100·400·500mg) of Pfizer Korea’s new drug for Ph+ CML Bosulif on the 12th. The drug is now indicated for the treatment of newly diagnosed chronic Ph+ CML or chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. Bosulif is a second-generation treatment that is t